School of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan, People's Republic of China.
Center for Drug Safety Evaluation, Shandong New Time Pharmaceutical Co., Ltd., Linyi, People's Republic of China.
Int J Nanomedicine. 2022 Sep 8;17:4039-4057. doi: 10.2147/IJN.S379736. eCollection 2022.
To improve the dissolution and bioavailability of the component-based Chinese medicine of leaves (GBCCM), a novel nanocrystalline solid dispersion of GBCCM (GBCCM NC-SD) was first prepared.
GBCCM mainly containing high pure flavonoid aglycones (FAs) and terpenoid lactones (TLs) was used as the model drug. PVP K30 and SDS were used as solubilizers, combined stabilizers and carriers, and GBCCM NC-SD was prepared by high-pressure homogenization combined with freeze-dryer. Morphology and crystal characteristic of GBCCM NC-SD were analyzed. The dissolution and bioavailability evaluation were performed to investigate the feasibility of GBCCM NC-SD by in vitro dissolution and in vivo integrated pharmacokinetic models.
After homogenizing for 30 cycles under the pressure of 650 bar and freeze-drying, GBCCM NC-SD with uniform quality would be obtained. The particle size, PDI and zeta potential were found to be 335.9 ± 32.8 nm, 0.29 ± 0.02 and -28.4 ± 0.7 mV respectively. Based on charged aerosol detector (CAD) technology, a new chromatographic method for simultaneous detection of eight components in GBCCM was developed. In vitro drug release study showed that the cumulative dissolution of FAs and TLs in GBCCM NC-SD increased from 12.77% to 52.92% (P < 0.01) and 90.91% to 99.21% (P < 0.05) respectively. In comparison with physical mixture of GBCCM and stabilizer (PM), the integrated pharmacokinetics AUC of FAs and TLs in GBCCM NC-SD were significantly increased (P < 0.05), and the T of TLs was also significantly prolonged (P < 0.05).
This study demonstrated that novel GBCCM NC-SD was prepared using Polyvinylpyrrolidone K30 (PVP K30) and Sodium dodecyl sulfate (SDS) as a synergetic stabilizer and also provided a feasible way to improve the dissolution and oral bioavailability of poorly soluble candidate antihypertensive drugs.
为提高中药叶(GBCCM)的成分的溶解性和生物利用度,首次制备了一种新型的 GBCCM 纳米晶固体分散体(GBCCM NC-SD)。
以高纯度黄酮苷元(FAs)和萜烯内酯(TLs)为主要成分的 GBCCM 为模型药物。采用 PVP K30 和 SDS 作为增溶剂、联合稳定剂和载体,通过高压匀质结合冷冻干燥法制备 GBCCM NC-SD。分析 GBCCM NC-SD 的形态和晶体特征。通过体外溶出和体内整合药代动力学模型进行溶出和生物利用度评价,考察 GBCCM NC-SD 的可行性。
在 650 巴压力下匀化 30 个循环并冷冻干燥后,可得到质量均匀的 GBCCM NC-SD。粒径、PDI 和 Zeta 电位分别为 335.9±32.8nm、0.29±0.02 和-28.4±0.7mV。基于带电气溶胶检测(CAD)技术,建立了一种同时检测 GBCCM 中 8 种成分的新色谱方法。体外药物释放研究表明,FA 和 TLs 在 GBCCM NC-SD 中的累积溶出度分别从 12.77%增加到 52.92%(P<0.01)和 90.91%增加到 99.21%(P<0.05)。与 GBCCM 与稳定剂的物理混合物(PM)相比,GBCCM NC-SD 中 FA 和 TLs 的整合药代动力学 AUC 显著增加(P<0.05),TLs 的 T 也显著延长(P<0.05)。
本研究表明,采用聚乙烯吡咯烷酮 K30(PVP K30)和十二烷基硫酸钠(SDS)作为协同稳定剂制备了新型 GBCCM NC-SD,为提高难溶性候选降压药物的溶解性和口服生物利用度提供了一种可行的方法。